Glenmark gets USFDA approval for anti-bacterial drug
The product is the therapeutic equivalent of Zyvox tablets, 600 mg of Pharmacia and Upjohn Company, a subsidiary of Pfizer, the company said.
Glenmark Pharmaceuticals has received the final nod from the US health regulator for a generic version of anti-bacterial drug Zyvox.
"Glenmark Pharmaceuticals Inc, USA, has been granted final approval by the US Food and Drug Administration (USFDA) for the Linezolid tablets, 600 milligram (mg)," Glenmark Pharmaceuticals said in a statement.
The product is the therapeutic equivalent of Zyvox tablets, 600 mg of Pharmacia and Upjohn Company, a subsidiary of Pfizer, it added.
ALSO READ: Glenmark announces settlement of patent litigation over anti-depressant drug
According to IMS Health sales data for the 12 months to October 2015, Zyvox tablets, 600 mg, achieved annual sales of around $447.6 million (approximately Rs 2,968.04 crore), Glenmark said.
Zyvox is an anti-bacterial drug marked for adults and children for treatment of infections such as pneumonia, complicated skin and skin structure infections, including diabetic foot infections.
With Tuesday's approval, the company's current portfolio consists of 104 products authorised for distribution in the US marketplace and 62 Abbreviated New Drug Applications (ANDA) pending approval with USFDA.
At 1206 hours, the shares of Glenmark Pharmaceuticals were trading up 1.36% or Rs 12.60 at Rs 940.00 intraday on BSE.